Patents by Inventor William Kingston Warburton

William Kingston Warburton has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 4012377
    Abstract: There are described new compounds of formula ##STR1## in which E is selected from the group consisting of residues of formula ##STR2## in which R" is selected from the group consisting of amino, vinyl, allyl, ethynyl, C.sub.1 -C.sub.5 alkyl, C.sub.1 -C.sub.5 alkoxy, or C.sub.1 -C.sub.5 alkylthio or a C.sub.1 -C.sub.5 alkyl group susbstituted by at least one halogen atom; and hydrogen; in which R.sup.1 and R.sup.2 are each selected from the group consisting of hydrogen, halogen, methyl and ethyl; and R' is selected from substituted phenyl when R" is other than hydrogen, and phenyl, thienyl and substituted phenyl and thienyl when R" is hydrogen.The compounds are useful in the control of parasites.Certain of the compounds have antimicrobial properties.
    Type: Grant
    Filed: March 7, 1975
    Date of Patent: March 15, 1977
    Assignee: Glaxo Laboratories Limited
    Inventors: John Anthony Claisse, Gordon Ian Gregory, William Kingston Warburton
  • Patent number: 3991067
    Abstract: 1,2,4-Oxadiazoles having as 3- and 5-substituents a hydrogen atom, an aliphatic, cycloaliphatic, araliphatic, aryl or heterocyclic group, or a carbamoyl group of the formula -- CONR.sup.1 R.sup.2 where R.sup.1 & R.sup.2 which can be the same or different, are hydrogen atoms or aliphatic, cycloaliphatic, araliphatic or aryl groups or, taken with the N atom, a heterocvolic ring; provided that at least one of the 3- or 5-substituents is an N-substituted carbamoyl group. Antimicrobial activity, and particularly antiviral, antiparasitic and antibacterial activity is shown in this group. The corresponding oxadiazolins are also described and are useful intermediates in the preparation of the oxadiazoles.
    Type: Grant
    Filed: November 13, 1973
    Date of Patent: November 9, 1976
    Assignee: Glaxo Laboratories Limited
    Inventors: Gordon Ian Gregory, William Kingston Warburton, Peter William Seale